Dignitana are adressing unmet medical needs. We see that the long term value is clouded by short term uncertainty. The fact that Dignitana continued to show strong growth in the first quarter and managed to sign a new master contract in the US which must be a strong signal for continued growth when the Covid -19 situation clears up. We are reiterating our positive view with a base case of SEK 11 per share.